Psychiatric Comorbidities in Patients with Idiopathic Intracranial Hypertension: A Prospective Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background and Objectives Psychiatric disease is a frequent comorbidity in idiopathic intracranial hypertension (IIH) and has been associated with a poor subjective outcome. No prospective studies have investigated psychiatric comorbidities in new-onset IIH. Our primary aim was to investigate disease severity in IIH depending on comorbid psychiatric disease. Important secondary outcomes were disease severity after 6 months and prevalence of psychiatric diseases in IIH.

Methods This prospective, observational cohort study consecutively included patients with clinically suspected, new-onset IIH from 2 headache centers. A standardized diagnostic workup was completed to confirm or exclude IIH according to the revised Friedman criteria: semi-structured interview, neurologic and neuro-ophthalmologic examination, lumbar puncture with opening pressure (OP), and neuroimaging. Exclusion criteria were known IIH, secondary intracranial hypertension, missing data, and pregnancy. Disease severity was evaluated based on papilledema, visual fields, OP, and headache in patients with IIH without psychiatric disease (IIH−P) compared with patients with IIH with psychiatric disease (IIH+P). A blinded neuro-ophthalmologist assessed visual outcomes. Age- and sex-matched prevalence rates of psychiatric diseases in the general population were found in national reports.

Results A total of 258 patients were screened; 69 were excluded. A total of 189 patients with clinically suspected IIH were then evaluated with the diagnostic workup and IIH was confirmed in 111 patients (58.7%). A total of 45% of patients with IIH had a psychiatric comorbidity. Visual fields were worse in patients with IIH+P at baseline (−8.0 vs −6.0 dB; p = 0.04) and after 6 months (−5.5 vs −4.0 dB; p < 0.01) compared with IIH−P. Highly prevalent psychiatric disorders were major depressive disorder (24.3%; n = 27), anxiety or stress-related disorders (24.3%; n = 27), and emotionally unstable personality disorder (6.3%; n = 7). Substance abuse (1.8%), schizophrenia (0.9%), and bipolar disorder (0.9%) were rare. In the general population, prevalence estimates of major depressive disorder and emotionally unstable personality disorder were 1.8%–3.3% and 2%, respectively.

Discussion Visual fields were significantly worse at baseline and 6 months in IIH+P compared with IIH−P. Psychiatric comorbidities, particularly depression and emotionally unstable personality disorder, were highly prevalent in IIH. Increased awareness of psychiatric disease as a marker for worse visual status may improve patient care.
OriginalsprogEngelsk
TidsskriftNeurology
Vol/bind99
Udgave nummer2
Sider (fra-til)199-208
ISSN0028-3878
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The study was funded by the Candys Foundation (2015–146), Lundbeck Foundation (ID R-276-2018-403-4), and Odense University Hospital and Rigshospitalet funds (ID 25-A1320, 69-A3346, e-fond 177). None of the funders was involved in the design or planning of the study, data collection, data analysis, data interpretation, or the drafting of the manuscript.

Funding Information:
J. Korsbaek received funding from Candys Foundation and the Lundbeck Foundation during the conduct of the study. D. Beier reports participating in clinical trials, serving on advisory or speaker boards for Novartis, Eli Lilly, Lundbeck, and Teva outside the submitted work (migraine), and receiving grants from Odense University Hospital and Rigshospitalet, University of Copenhagen, during the conduct of the study. S.M. Hagen reports receiving grants from Fight for Sight, Denmark, and the Synoptik Foundation during the conduct of the study. L.D. Molander reports no conflicts of interest. R.H. Jensen reports participating in clinical trials, serving on advisory or speaker boards for Lundbeck, Novartis, TEVA, Allergan, Lionheart-Pharmaceuticals, and Eli Lilly outside the submitted work (other headache disorders), and receiving grants from the Lundbeck Foundation, Candys Foundation, and the Odense University Hospital-Rigshospitalet during the conduct of the study and the Novo Nordisk Foundation and Tryg Foundation outside the submitted work. Go to Neurology.org/N for full disclosures.

Publisher Copyright:
© 2022 American Academy of Neurology.

ID: 346064054